The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Action Update, January 2026: Approvals, Acceptance, and Clearance NeurologyLive Clinical Neurology News and Neurology Expert Insights FDA User Fees for FY 2026 Alba 2024 FDA approvals exceed average number but have lower sales projections FDA approvals February 2026 March Roundup of FDA Approvals in Oncology: 4 Decisions to Know OncLive